ALT•benzinga•
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Summary
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 14, 2025 by benzinga